Aurora Cannabis Inc (NYSE:ACB) Wins A Second Order From Luxembourg Healthy Ministry To Supply Medical Cannabis To de la Pharmacie et des Medicaments

Aurora Cannabis Inc (NYSE:ACB) Wins A Second Order From Luxembourg Healthy Ministry To Supply Medical Cannabis To de la Pharmacie et des Medicaments

Aurora Deutschland, a subsidiary of Aurora Cannabis Inc (NYSE:ACB), has bagged a second order from Luxembourg Health Ministry. Under this exclusive deal, the company will supply medical cannabis to de la Pharmacie et des Medicaments, a division of Luxembourg. The company is proud to win this order in a public tender.

The second order confirms the trust reposed in Aurora as a supplier of quality cannabis. It shows the commitment of Aurora to work with regulators and local governments in the restricted markets.

Chief Global Business Development Officer, Neil Belot of Aurora said the company is pleased to get selected as an exclusive supplier of medical cannabis to the Luxembourg government. Another milestone to its credit includes recent selection as one of the three firms to begin manufacture of cannabis in Germany.

Access to high quality cannabis

Associate Director (Business Development) of Aurora, Maximilian Weinberg said the company is well positioned to capitalize on the growing demand with early mover advantage to grow medical cannabis. He is proud of the efforts put in by the team to accomplish the goal. The company is looking forward to provide access to good quality medical cannabis to the Luxembourg patients.

Tight trading range

The stock of Aurora is moving in a tight trading range. The company expects to release Q1 earnings on May 14, 2019 and the stock could see some action. It provides a critical update on the prospects of Aurora to investors.

Aurora is expected to post a robust growth in revenues in Q1 2019 backed by the execution of medical and cannabis strategies. The catalysts to the growth include the introduction of value added derivative products, and the launch of derivative products in the global markets. It supports growth in revenues and better margins.

Aurora achieved significant progress in clinical case studies. The company expects to begin 40 medical case and clinical trials. It is also progressing seven preclinical trials. The outcome of the clinical trials expects to strengthen the position of Aurora as a leader in medical space in the international and in the domestic markets. It expects to capture a major market share in the international and in Canadian markets.

Published at Tue, 14 May 2019 12:01:23 +0000

Leave a Reply

Your email address will not be published. Required fields are marked *